Stock Events

Evotec 

€6.03
256
+€0.08+1.26% Wednesday 15:32

Statistics

Day High
6.08
Day Low
6
52W High
22.67
52W Low
5.21
Volume
0
Avg. Volume
87
Mkt Cap
3.19B
P/E Ratio
451.38
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6NovExpected
Q1 2024
Q2 2024
Next
-0.53
-0.36
-0.2
-0.04
Expected EPS
-0.0433459653722656
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EVT.VI. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Show more...
CEO
Dr. Werner Lanthaler M.B.A., MBA, MPA, Ph.D.
Employees
4715
Country
DE
ISIN
DE0005664809

Listings